Enhertu Granted Priority Review in the US for Patients With HER2-Positive Metastatic Breast Cancer Treated With a Prior Anti-HER2-Based RegimenBusiness Wire • 01/17/22
ENHERTU® Granted Priority Review in the U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based RegimenBusiness Wire • 01/17/22
AstraZeneca Booster Shot Generates Strong Immune Response Against Variants Including OmicronForbes • 01/13/22
AstraZeneca's COVID-19 Vaccine Booster Against Omicron, Delta - New Data Supports UseBenzinga • 01/13/22
AstraZeneca Aims to Redefine Liver, Biliary Tract and Prostate Cancer Treatment With Practice-Changing IMFINZI® (durvalumab) and LYNPARZA® (olaparib) Data at ASCO GI and GUBusiness Wire • 01/13/22
Scorpion Therapeutics Enters Agreement with AstraZeneca to Discover, Develop and Commercialize Novel Cancer Treatments Against ‘Undruggable' TargetsBusiness Wire • 01/13/22
Scorpion Therapeutics, AstraZeneca Ink Precision Medicines Pact For Hard-To-Target Cancer ProteinsBenzinga • 01/13/22
Fusion Pharmaceuticals Announces Nomination of First Targeted Alpha Therapy Candidate in Collaboration with AstraZeneca to Advance into IND-Enabling Studies for Phase 1 DevelopmentPRNewsWire • 01/10/22
AstraZeneca and Neurimmune sign deal to develop and commercialise treatment for fatal condition ATTR-CMProactive Investors • 01/07/22
Ovid Therapeutics Expands Its Anti-Epileptic Franchise With AstraZeneca Licensing PactBenzinga • 01/03/22
Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based RegimenBusiness Wire • 12/28/21
Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should KnowZacks Investment Research • 12/25/21